What does Sterop Overseas do?

Sterop Overseas is a wholesaler in Anderlecht. Public Limited, started on 27 January 1979, 1 establishment.

What is the address of Sterop Overseas?

The registered office of Sterop Overseas is located at Researchdreef 20, 1070 Anderlecht.

Is Sterop Overseas still active?

Yes. According to the CBE (31 October 2026) Sterop Overseas is active, legal situation “Normale toestand”, started on 27 January 1979.

Is Sterop Overseas registered on Peppol?

Yes, Sterop Overseas is registered on the Peppol network with ID 0208:0419184411.

What is the enterprise number of Sterop Overseas?

The enterprise number of Sterop Overseas is BE0419184411.

When was Sterop Overseas founded?

Sterop Overseas was founded on 27 January 1979.

Who are the directors of Sterop Overseas?

According to the 2025 annual accounts, the directors of Sterop Overseas are: Sophie EYKERMAN.

Is Sterop Overseas a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 January 1979; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Sterop Overseas make in 2025?

Sterop Overseas posted a profit after taxes of € 481,216 in financial year 2025.

What is the revenue of Sterop Overseas?

As a small company, Sterop Overseas is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 931,763.

How much does an employee at Sterop Overseas earn?

The average wage cost per full-time employee at Sterop Overseas was € 49,200 in 2024: staff costs of € 265,575 for 5.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

Sterop Overseas (Public Limited) - Anderlecht

Dossier Sterop Overseas, printed on 31 October 2026 from databakkes.be/en/0419184411/sterop-overseas. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Sterop Overseas from Anderlecht, company number BE0419184411, closed financial year 2025 with a result of € 481,216 after tax. For that financial year Sterop Overseas recorded a gross margin of € 931,763 and equity of € 2.3 million. Compared with financial year 2024, the result moved from € 1 million to € 481,216. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 23, 2026.

What it is worth Growing

€ 2.3 million

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 481,216

▼ 53% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.3 million

▲ € 1.2 million vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 480,000 paid out

100 % of the profit went to the shareholders, mostly to PHARMASOVA (100 % of the shares). That is where the money ends up.

People and assets in 2025

Wage cost

€ 246,410

▼ 7% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

€ 350,000

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 213,765

▼ 76% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 171,884

▲ 8% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,280,726 Gross margin 2022: € 1,280,726 First fiscal year in the series	€ 1,259,038 Gross margin 2023: € 1,259,038 ▼ 2% vs 2022 (€ 1,280,726) Unfavourable step	€ 1,869,081 Gross margin 2024: € 1,869,081 ▲ 48% vs 2023 (€ 1,259,038) Favourable step	€ 931,763 Gross margin 2025: € 931,763 ▼ 50% vs 2024 (€ 1,869,081) Unfavourable step	▼ 50%
Profit after taxes	€ 336,289 Profit after taxes 2022: € 336,289 First fiscal year in the series	€ 460,854 Profit after taxes 2023: € 460,854 ▲ 37% vs 2022 (€ 336,289) Favourable step	€ 1,031,504 Profit after taxes 2024: € 1,031,504 ▲ 124% vs 2023 (€ 460,854) Favourable step	€ 481,216 Profit after taxes 2025: € 481,216 ▼ 53% vs 2024 (€ 1,031,504) Unfavourable step	▼ 53%
Equity	€ 2,344,934 Equity 2022: € 2,344,934 First fiscal year in the series	€ 2,345,788 Equity 2023: € 2,345,788 Unchanged (€ 2,344,934) Favourable step	€ 2,347,292 Equity 2024: € 2,347,292 Unchanged (€ 2,345,788) Favourable step	€ 2,348,508 Equity 2025: € 2,348,508 Unchanged (€ 2,347,292) Favourable step
Total debts	€ 3,690,900 Total debts 2022: € 3,690,900 First fiscal year in the series	€ 2,976,692 Total debts 2023: € 2,976,692 ▼ 19% vs 2022 (€ 3,690,900) Favourable step	€ 2,881,897 Total debts 2024: € 2,881,897 ▼ 3% vs 2023 (€ 2,976,692) Favourable step	€ 1,726,379 Total debts 2025: € 1,726,379 ▼ 40% vs 2024 (€ 2,881,897) Favourable step	▼ 40%
Cash	€ 859,249 Cash 2022: € 859,249 First fiscal year in the series	€ 516,144 Cash 2023: € 516,144 ▼ 40% vs 2022 (€ 859,249) Unfavourable step	€ 87,657 Cash 2024: € 87,657 ▼ 83% vs 2023 (€ 516,144) Unfavourable step	€ 1,267,558 Cash 2025: € 1,267,558 ▲ € 1.2 million vs 2024 (€ 87,657) Favourable step	▲ € 1.2 million
Retained profit	€ 2,264,934 Retained profit 2022: € 2,264,934 First fiscal year in the series	€ 2,265,788 Retained profit 2023: € 2,265,788 Unchanged (€ 2,264,934) Favourable step	€ 2,267,292 Retained profit 2024: € 2,267,292 Unchanged (€ 2,265,788) Favourable step	€ 2,268,508 Retained profit 2025: € 2,268,508 Unchanged (€ 2,267,292) Favourable step
Dividend	€ 330,000 Dividend 2022: € 330,000 First fiscal year in the series	€ 460,000 Dividend 2023: € 460,000 ▲ 39% vs 2022 (€ 330,000) Unchanged	€ 1,030,000 Dividend 2024: € 1,030,000 ▲ 124% vs 2023 (€ 460,000) Unchanged	€ 480,000 Dividend 2025: € 480,000 ▼ 53% vs 2024 (€ 1,030,000) Unchanged	▼ 53%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 150,000 Bank debt 2023: € 150,000 Unchanged (€ 0) Unfavourable step	€ 350,000 Bank debt 2024: € 350,000 ▲ 133% vs 2023 (€ 150,000) Unfavourable step	€ 350,000 Bank debt 2025: € 350,000 Unchanged (€ 350,000) Unchanged
Balance sheet total	€ 6,035,834 Balance sheet total 2022: € 6,035,834 First fiscal year in the series	€ 5,322,480 Balance sheet total 2023: € 5,322,480 ▼ 12% vs 2022 (€ 6,035,834) Unchanged	€ 5,229,189 Balance sheet total 2024: € 5,229,189 ▼ 2% vs 2023 (€ 5,322,480) Unchanged	€ 4,074,887 Balance sheet total 2025: € 4,074,887 ▼ 22% vs 2024 (€ 5,229,189) Unchanged	▼ 22%
Employees (FTE)	4.7 Employees (FTE) 2022: 4.7 First fiscal year in the series	-	5.4 Employees (FTE) 2024: 5.4 First fiscal year in the series	-

Key figures of Sterop Overseas, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Sterop Overseas?

What happened at Sterop Overseas in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 23, 2026 New annual accounts for financial year 2025: profit of € 481,216 (▼ 53% vs 2024). filed late Source: NBB ↗
2026 Sophie EYKERMAN became a director. NBB
Jan 27, 1979 Start of the company according to the CBE. KBO
Jan 25, 1979 New establishment in Anderlecht. KBO

In short

From € 336,289 profit in 2022 to € 481,216 profit in 2025.

Paid € 821,991 in corporate taxes since 2022.

Best year ever: 2024, with € 1 million profit.

On average € 346,100 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

PHARMASOVA 100%

The stake of PHARMASOVA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Sterop Overseas

Behind Sterop Overseas is Sophie EYKERMAN. The shares are held by PHARMASOVA (100%).

Directors

According to the 2025 annual accounts

Sophie EYKERMAN

Managing director

since 2026

Shareholders

PHARMASOVA

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Researchdreef 20

1070 Anderlecht

2.016.342.166

Scheutlaan 46 5

1070 Anderlecht

Active since 25 January 1979

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Reckitt et Colman Foundation

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0419.184.411

VAT number

BE 0419.184.411

Registered office

Researchdreef 20, 1070 Anderlecht

Names & denominations

Sterop Overseas

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

27 January 1979

Peppol

Active · Active since 12 Mar 2026

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

Groothandel in chemische producten voor industrieel gebruik

Groothandel in chemische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

Sterop Overseas

Financials

What happened to Sterop Overseas?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions